Shopping Cart
- Remove All
Your shopping cart is currently empty
Cimigenoside
Cimigenoside, a constituent of Asclepias, is a γ-secretase inhibitor that inhibits the proliferation or metastasis of human breast cancer cells via the γ-secretase/Notch axis.
Catalog No. T6S1676Cas No. 27994-11-2
Select Batch
Purity:99.81%
Contact us for more batch information
Cimigenoside
Catalog No. T6S1676Cas No. 27994-11-2
Cimigenoside, a constituent of Asclepias, is a γ-secretase inhibitor that inhibits the proliferation or metastasis of human breast cancer cells via the γ-secretase/Notch axis.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $31 | In Stock | |
| 5 mg | $70 | In Stock | |
| 10 mg | $101 | In Stock | |
| 25 mg | $170 | In Stock | |
| 50 mg | $251 | In Stock | |
| 100 mg | $373 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $108 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Cimigenoside"
Valproic acid sodium salt
Cited
Sodium Valproate
T16021069-66-5
Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.
- $42
Size
QTY
CitedValproic acid sodium salt Cited
Sodium Valproate
T16021069-66-5
Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.
- $42
Size
QTY
CitedValproic acid sodium salt Cited
Sodium Valproate
T16021069-66-5
Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.
- $42
Size
QTY
CitedValproic acid sodium salt Cited
Sodium Valproate
T16021069-66-5
Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.
- $42
Size
QTY
CitedValproic acid sodium salt Cited
Sodium Valproate
T16021069-66-5
Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.
- $42
Size
QTY
CitedValproic acid sodium salt Cited
Sodium Valproate
T16021069-66-5
Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.
- $42
Size
QTY
CitedValproic Acid Cited
VPA, Sodium valproate, Depakine, 2-Propylvaleric Acid, 2-Propylpentanoic Acid
T706499-66-1
Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that inhibits HDAC1 activity, induces HDAC2 degradation, and is orally active. Valproic Acid can be used in epilepsy and bipolar disorder research.
- $50
Size
QTY
CitedValproic Acid Cited
VPA, Sodium valproate, Depakine, 2-Propylvaleric Acid, 2-Propylpentanoic Acid
T706499-66-1
Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that inhibits HDAC1 activity, induces HDAC2 degradation, and is orally active. Valproic Acid can be used in epilepsy and bipolar disorder research.
- $50
Size
QTY
CitedValproic Acid Cited
VPA, Sodium valproate, Depakine, 2-Propylvaleric Acid, 2-Propylpentanoic Acid
T706499-66-1
Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that inhibits HDAC1 activity, induces HDAC2 degradation, and is orally active. Valproic Acid can be used in epilepsy and bipolar disorder research.
- $50
Size
QTY
CitedValproic Acid Cited
VPA, Sodium valproate, Depakine, 2-Propylvaleric Acid, 2-Propylpentanoic Acid
T706499-66-1
Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that inhibits HDAC1 activity, induces HDAC2 degradation, and is orally active. Valproic Acid can be used in epilepsy and bipolar disorder research.
- $50
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
| Description | Cimigenoside, a constituent of Asclepias, is a γ-secretase inhibitor that inhibits the proliferation or metastasis of human breast cancer cells via the γ-secretase/Notch axis. |
| Molecular Weight | 620.81 |
| Formula | C35H56O9 |
| Cas No. | 27994-11-2 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/ml (96.65 mM)  Ethanol: Soluble Pyridine, Methanol, etc.: Soluble | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Cimigenoside | purchase Cimigenoside | Cimigenoside cost | order Cimigenoside | Cimigenoside chemical structure | Cimigenoside formula | Cimigenoside molecular weight
- TOP
Feedback
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.